Our Purpose

Serving Science

We are focused on providing premium quality products and a superior cell culture experience for our customers. We understand how important cell culture is to the success of life science research. These cells are what enable the scientific breakthroughs that extend and save lives. Your ability to generate quality data is dependent upon using tested, proven products.


A trusted source for precision cell culture solutions that feed scientific breakthrough.

Curing disease starts with science

In a perfect world, all scientific experiments move forward without confounding variables. While perfection isn’t possible, mitigating risk by demanding only the highest quality cell culture products will facilitate scientific breakthroughs. Working together, we can speed up discovery and cure disease by ensuring that our products meet the demanding requirements of those fueling today’s increasingly complex scientific innovations.

At the core of cell science

We are elevating consistency and authenticity in cell culture. We believe we can accomplish this by delivering superior products through a transparent, consistent and proven supply chain that eliminates variability for you, our customers.

“For us to achieve our mission of providing the highest quality cell culture solutions to feed scientific breakthrough we must be unrelenting in the pursuit of innovation of product and process.”

– Chief Executive Officer, David Sheehan

Leadership Team

Nucleus Biologics David Sheehan
David SheehanPresident, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Nucleus Biologics Sanjay Popat
Sanjay PopatCFO

Sanjay Popat is the CFO at Nucleus Biologics. Sanjay has extensive experience in both the life sciences space and investments. Prior to joining Nucleus Biologics, Sanjay was the CFO at Tavistock Life Sciences, which is a life sciences investment arm of Tavistock Group (an international private investment company with 200 portfolio companies across 11 countries) and was responsible for all financial and operational matters, as well as strategic high value investments at the Tavistock Group level, including their investment in Australian Agriculture Company. In his role at Tavistock Life Sciences Sanjay has served as CEO, CFO and controller at several portfolio companies, including Iapyx Inc, CovX Research and Kalypsys Inc. Prior to this position, Sanjay held various positions at UBS Global Asset Management, Insight Management Associates and other investment companies. Sanjay holds a master’s degree in business administration from the Illinois Institute of Technology and a bachelor’s degree in accountancy from Gujarat University.

Daniel Schroen, PhDVice President, Sales

Dan has been in the cell biology field in one form or another since 1989, with roles ranging from bench scientist to commercial leadership. Prior to Nucleus Biologics, he served as Vice President, Sales and Marketing at Cell Applications, Inc. Before that, he spent a good portion of his career at life science companies now under the flagship of Thermo Fisher Scientific, where he cut his teeth at product management, business development, commercialization and strategic business initiatives. Dr. Schroen obtained his BS and PhD at Illinois State University, where his work on immune cell behavior earned the Clarence W. Sorensen Distinguished PhD Dissertation. Postdoctoral Fellowships followed at Dartmouth Medical School and the University of Massachusetts.

Nucleus Biologics Alyssa Master
Dr. Alyssa MasterSenior Manager of Science and Applications

Dr. Alyssa Master has ten years of laboratory research experience including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. In graduate school, Alyssa was the recipient of both the Medtronic Fellowship and the NIH Ruth L. Kirschstein Predoctoral Fellowship. During these fellowships, Alyssa developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Following graduate school, Alyssa completed a postdoctoral fellowship in the Department of Pharmacology at the University of Illinois at Chicago Medical School and a postdoctoral fellowship in the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill School of Pharmacy. Alyssa has a PhD in Biomedical Engineering from Case Western Reserve University.

Katie CollinsMarketing Director and Business Development

Katie Collins has worked in various roles within the biomedical research field and most recently worked as the Development Director at the J. Craig Venter Institute. After 15 years working for biomedical research institutions, she started her own consulting company, providing business development and marketing strategies for both for-profit and nonprofit start-ups looking to make a difference. Katie was a scholarship swimmer at Penn State University and sits on various nonprofit boards in San Diego.

Board of Directors

Neil ReismanChairman of the Board

Neil is a managing director and member of the Tavistock Group Board of Directors. Tavistock Group has investments in more than 200 companies across 11 countries, with investment sectors including real estate, hospitality, restaurants, sports, energy, retail, life sciences, agriculture, and finance. Neil works with various portfolio companies and sits on the board of AACo. Prior to that, he chaired the Investment Committee, managed the office of General Counsel and the office of CFO and previously had executive operational roles at several biotech companies in San Diego. Neil has 30 years of business experience with emphasis on finance, operations, legal, tax, and mergers and acquisitions. Neil received his JD in 1986 from the University of Pennsylvania Law School and his BS in Accountancy in 1983 from the University of Illinois. Neil is also a CPA.

Kieran T. GallahueDirector

Kieran was Chairman of the Board and Chief Executive Officer of CareFusion Corporation from 2011 until March 2015 when it was sold to Becton Dickinson. Previously, Kieran joined ResMed, Inc. in 2003 as President and Chief Operating Officer of the Americas, was promoted to the role of President and Chief Operating Officer of ResMed Global in 2004, and Chief Executive Officer and director in 2008. Kieran also served on the board of Volcano Corporation until 2015. Prior to 2002, he held various marketing, sales and financial positions within Nanogen, Inc., Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company. Kieran currently sits on the board of directors of Edwards Lifesciences and Intersect ENT. Kieran has a bachelor's degree from the Rutgers University College of Agricultural and Biological Sciences and an MBA from Harvard Business School.

Dr. Rodney LappeDirector

Rodney served as the Chief Scientific Officer of CovX Research LLC. Rodney joined CovX in January 2004. From January 2004 to December 2011, he was Group Senior Vice President, Pfizer Worldwide Research and Development at CovX Research LLC. He joined Pfizer with the CovX acquisition in 2008. Rodney has a strong understanding of pharmacology, a clear strategic scientific vision and extensive experience in international drug discovery collaborations. From 2000 to 2002, Rodney served as Vice President for cardiovascular and metabolic diseases at Pharmacia. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth Laboratories, Rorer Central Researh, CIBA Geigy Pharmaceuticals and Searle Pharmaceuticals. He has been the Chairman of Mirati Therapeutics, Inc. since July 2013 and its Director since June 27, 2012. He has been a Director of MethylGene Inc., since June 27, 2012. He previously served as a Director of Neuren Pharmaceuticals Ltd.. Rodney received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Nucleus Biologics David Sheehan
David SheehanPresident, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Dane FitzGibbonDirector

Dane was appointed Head of Strategy & Growth for the Australian Agricultural Company (AACo) in 2017. AACo is a $1 billion (AUD) publicly listed company that is the largest and oldest beef producer in Australia. He was previously a Managing Director at UBS Investment Bank, and has more than 17 years' experience in the banking and finance industry. He brings insight from his current role in the beef cattle industry, and expertise from his financial and transaction advisory experience. Dane holds a Masters of Applied Finance and a Bachelor of Business from Queensland University of Technology.

Contact us for more information